On June 10, 2022 3B Pharmaceuticals GmbH (3BP) reported that a Platinum Sponsor of the 6th Theranostics World Congress1 which will be held from 24th to 26th June at the RheinMain CongressCenter Wiesbaden, Germany (Press release, 3B Pharmaceuticals, JUN 10, 2022, View Source [SID1234615919]). The event celebrates 25 years of Peptide Receptor Radionuclide Therapy (PRRT) in Germany and provides the opportunity for mutual exchange on scientific and clinical development in Theranostics and Radiomolecular Precision Oncology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The symposium entitled "3BP’s innovation alliances-Tailoring compounds to the needs of theranostic radiopharmaceuticals" will take place on June 25, from 09:00 am to 09:55 am CEST. Clinical and industry expert chairs and speakers will be giving insightsinto the translation from early development stages towards successful clinical application of 3BP’s innovative peptide-based radiopharmaceuticals.
"We are proud to witness the successful translation of our peptide tracers into clinical development and how the first patients benefit from treatment with our innovative compounds" said Ulrich Reineke, Managing Director of 3BP. "The innovation alliances with our equally enthusiastic development partners who share our passion for radiopharmaceuticals are at the core of our mission to help patients suffering from cancer indications with high medical need."
Symposium & Speaker Details:
Dr. Ulrich Reineke will give the welcome address and the symposium will be opened by Dr. Christiane Smerling outlining 3BP’s discovery engine and the partnership with Fusion Pharmaceuticals. Dr. Antoine Attinger will give an insight into how radioligands can address hypoxic tumors as a cancer treatment strategy. Dr. Lindsey Rolfe will present first data from the phase 1/2 LuMIERE study on treatment of advanced or metastatic solid tumors using 177LuFAP-2286. The session will be chaired by Prof. Wolfgang Weber and John Carney.
The symposium is free to all conference attendees and breakfast will be provided. Speakers will be available for a Q&A session at the end of the event.